Quality of life as an outcome measure

被引:21
作者
Bulpitt, CJ
机构
关键词
quality of life; outcome measure; benefit:risk ratio; Sickness Impact Profile;
D O I
10.1136/pgmj.73.864.613
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
It is important to identify unknown and unquantified benefits and risks of therapeutic intervention that are reflected in the quality of life. This is especially important when the benefit : risk analysis is not clearly in favour of treatment. Quality of Life is defined and target areas identified. The steps in the measurements of quality of life are discussed, including the validity, repeatability and sensitivity to change of existing methods; their acceptability, analytical problems; the presentation of the results; and the use of the results in economic evaluations. The Sickness Impact Profile, the Nottingham Health Profile and the Quality of Well-Being scale are compared for the assessment of patients with angina. The advantages and disadvantages of each is discussed together with the results from a double-blind trial of treatment in angina where the Sickness Impact Profile was employed. Generic and disease-specific instruments are compared. The advantages and disadvantages of economic evaluations employing quality-of-life outcomes are discussed. Methods should be employed that withstand rigorous scientific evaluation. Both a health profile and a summary statistic such as a Health Status Index should be measured. If different treatments are to be compared, a randomised controlled trial should be employed. If the more expensive treatment is likely to be superior then costs should be collected and a cost-utility analysis performed.
引用
收藏
页码:613 / 616
页数:4
相关论文
共 20 条
[1]   THE SICKNESS IMPACT PROFILE - DEVELOPMENT AND FINAL REVISION OF A HEALTH-STATUS MEASURE [J].
BERGNER, M ;
BOBBITT, RA ;
CARTER, WB ;
GILSON, BS .
MEDICAL CARE, 1981, 19 (08) :787-805
[2]   THE EFFECTS OF ANTIHYPERTENSIVE THERAPY ON THE QUALITY-OF-LIFE [J].
CROOG, SH ;
LEVINE, S ;
TESTA, MA ;
BROWN, B ;
BULPITT, CJ ;
JENKINS, CD ;
KLERMAN, GL ;
WILLIAMS, GH .
NEW ENGLAND JOURNAL OF MEDICINE, 1986, 314 (26) :1657-1664
[3]  
FLETCHER A, 1988, LANCET, V2, P4
[4]   PRESSURE TO TREAT AND PRESSURE TO COST - A REVIEW OF COST-EFFECTIVENESS ANALYSIS [J].
FLETCHER, A .
JOURNAL OF HYPERTENSION, 1991, 9 (03) :193-198
[5]   QUALITY-OF-LIFE WITH 3 ANTIHYPERTENSIVE TREATMENTS - CILAZAPRIL, ATENOLOL, NIFEDIPINE [J].
FLETCHER, AE ;
BULPITT, CJ ;
CHASE, DM ;
COLLINS, WCJ ;
FURBERG, CD ;
GOGGIN, TK ;
HEWETT, AJ ;
NEISS, AM .
HYPERTENSION, 1992, 19 (06) :499-507
[6]   A QUANTITATIVE APPROACH TO PERCEIVED HEALTH-STATUS - A VALIDATION-STUDY [J].
HUNT, SM ;
MCKENNA, SP ;
MCEWEN, J ;
BACKETT, EM ;
WILLIAMS, J ;
PAPP, E .
JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH, 1980, 34 (04) :281-286
[7]   COST-EFFECTIVENESS ANALYSIS OF HYPERTENSION TREATMENT - A REVIEW OF METHODOLOGICAL ISSUES [J].
JOHANNESSON, M ;
JONSSON, B .
HEALTH POLICY, 1991, 19 (01) :55-78
[8]  
KAPLAN RM, 1976, HEALTH SERV RES, V11, P478
[9]   BENEFICIAL-EFFECTS OF PIMOBENDAN ON EXERCISE TOLERANCE AND QUALITY-OF-LIFE IN PATIENTS WITH HEART-FAILURE - RESULTS OF A MULTICENTER TRIAL [J].
KUBO, SH ;
GOLLUB, S ;
BOURGE, R ;
RAHKO, P ;
COBB, F ;
JESSUP, M ;
BROZENA, S ;
BRODSKY, M ;
KIRLIN, P ;
SHANES, J ;
KONSTAM, M ;
GRADMAN, A ;
MORLEDGE, J ;
CINQUEGRANI, M ;
SINGH, S ;
LEJEMTEL, T ;
NICKLAS, J ;
TROHA, J ;
COHN, JN .
CIRCULATION, 1992, 85 (03) :942-949
[10]   TREATMENT OF CHRONIC HEART-FAILURE - A REVIEW OF RECENT DRUG TRIALS [J].
LIPKIN, DP ;
POOLEWILSON, PA .
BRITISH MEDICAL JOURNAL, 1985, 291 (6501) :993-996